IS

Isofol Medical AB (publ)STO Isofol Medical Stock Report

Last reporting period 31 Dec, 2023

Updated 31 Oct, 2024

Last price

Market cap $B

0.042

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

ISOFOL.ST Stock Analysis

IS

Uncovered

Isofol Medical AB (publ) is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-33/100

Low score

Market cap $B

0.042

Dividend yield

110.42 %

Shares outstanding

161.51 B

Isofol Medical AB is a biotech company, which engages in the development of the cancer drug Arfolitixorin, intended primarily for the treatment of colorectal cancer. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-04-04. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The firm cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.

View Section: Eyestock Rating